Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising incidence of cancer
3.2.1.2 Increasing focus towards combination therapies
3.2.1.3 Rising R&D investments
3.2.1.4 Growing advancements in viral engineering
3.2.2 Industry pitfalls & challenges
3.2.2.1 Development of immunogenicity and resistance to the treatment
3.2.2.2 High cost and risk associated with the treatment
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Virus Type, 2021 - 2032 ($ Million)
5.1 Key trends
5.2 Herpes simplex virus (HSV)
5.3 Adenovirus
5.4 Vaccinia virus
5.5 Newcastle disease virus
5.6 Reovirus
5.7 Other virus types
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Million)
6.1 Key trends
6.2 Intratumoral
6.3 Intravenous
6.4 Other routes of administration
Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Million)
7.1 Key trends
7.2 Melanoma
7.3 Breast cancer
7.4 Lung cancer
7.5 Ovarian cancer
7.6 Prostate cancer
7.7 Other applications
Chapter 8 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Million)
8.1 Key trends
8.2 Hospitals & clinics
8.3 Cancer research institutes
8.4 Ambulatory surgical centers
8.5 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Amgen Inc.
10.2 Creative Biolabs
10.3 Daiichi Sankyo Company Limited
10.4 Genelux Corporation
10.5 Oncorus Inc.
10.6 Replismune Inc.
10.7 Siga Technologies
10.8 Sorrento Therapeutics Inc.
10.9 TILT Biotherapeutics
10.10 Viralytics Ltd.
